Biosense Webster, a Johnson & Johnson-owned company focused on cardiac arrhythmia treatment, announced that several of its catheter products have received FDA approval for a zero fluoroscopy workflow, according to an Aug. 4 news release.
The updated workflow approval suggests "that direct imaging guidance, such as ultrasound, may be used as an alternative to fluoroscopy," the release states.
The change in labeling that has now been approved by the FDA "improves safety, and efficiency of cardiac ablation procedures," Jasmina Brooks, president of Biosense Webster said in a statement. "As a result of this update, our teams can now proactively discuss the fluoroscopy alternative workflow with our customers to reinforce the benefits of the Biosense Webster portfolio of products."